Inflazome’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Inflazome is a biotech company that develops and commercializes molecular-targeted drug therapies for the treatment of inflammatory diseases. Read more

4 Followers on Owler
4 Followers on Owler
4 Followers on Owler
4 Followers on Owler

Inflazome is a biotech company that develops and commercializes molecular-targeted drug therapies for the treatment of inflammatory diseases. Read more

Matthew Cooper's photo - Co-Founder & CEO of Inflazome

Co-Founder & CEO

Matthew Cooper

CEO Approval Rating

89/100

Founded:

2016

Est. Annual Revenue
Est. Employees

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Inflection Biosciences is one of Inflazome's top rivals. Inflection Biosciences is a Private company that was founded in 2012 in Blackrock, County Dublin. Inflection Biosciences competes in the Health Care Services industry. Compared to Inflazome, Inflection Biosciences has 23 more employees.

Medexus Pharma, Inc. is seen as one of Inflazome's biggest rivals. Medexus Pharma, Inc. was founded in 2012 in Chicago, Illinois. Like Inflazome, Medexus Pharma, Inc. also works within the Biotechnology field. Medexus Pharma, Inc. generates $1.7M more revenue than Inflazome.

Mesoblast Limited is one of Inflazome's top competitors. Mesoblast Limited was founded in 2004, and its headquarters is in Melbourne, Victoria. Like Inflazome, Mesoblast Limited also operates in the Biotechnology sector. Mesoblast Limited has 95 more employees than Inflazome.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 7 a good estimate for Inflazome's Employee count?

Acquisitions

No recent acquisitions found related to Inflazome

Inflazome Funding History

$17M$63M$64M

Since Inflazome was founded in 2016, it has participated in 3 rounds of funding. In total Inflazome has raised $64.0M. Inflazome's last funding round was on Mar 2019 for a total of $1.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Grant
Mar 2019
$1M
Series B
Nov 2018
$46M

Forbion

Series A
Sep 2016
$17M

Since Inflazome was founded in 2016, it has participated in 3 rounds of funding. In total Inflazome has raised $64.0M. Inflazome's last funding round was on Mar 2019 for a total of $1.0M

Investments

No recent investments found related to Inflazome

Inflazome News

September 21, 2020SiliconRepublic

Inflazome snapped up in 380m deal with Swiss pharma giant

Dublin-based Inflazome has agreed to transfer its pharma portfolio to Swiss multinational pharma gian... See more »
September 21, 2020BioPharma Dive

Roche buys Inflazome as pharma interest in targeting inflammation grows

The wide-ranging role of an inflammatory protein known as NLRP3 has made it a hot drug target - parti... See more »
July 15, 2020PharmaLeaders

FDA grants orphan drug designation for Inflazome's Inzomelid to treat cryopyrin-associated periodic syndromes

Orphan Drug Designation is an important regulatory milestone granted to drugs that are intended to tr... See more »
March 25, 2020BioPortfolio

Inzomelid completes Phase I studies and shows positive results in the treatment of CryopyrinAssociated Periodic Syndrome CAPS

The Phase I study demonstrated Inzomelid has an excellent safety tolerability and pharmacokinetic pro... See more »
February 27, 2020BioPortfolio

Inflazomes Somalix Demonstrates Positive Safety Tolerability and Pharmacodynamic Profile in its Phase I Study

Results from the firstinhuman study showed excellent safety tolerability and pharmacokinetics in heal... See more »
January 16, 2020PharmaTech

Inflazome to be Granted Patents in US and Europe

Inflazome, a biotech company based in Dublin, Ireland, has announced that the United States Patent an... See more »

Inflazome Press Releases

Inflazome Videos

Social Media

Headquarters

32 Kildare Street

Dublin, County Dublin

353-1-687-5002

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Inflazome is a biotech company that develops and commercializes molecular-targeted drug therapies for the treatment of inflammatory diseases. Inflazome was founded in 2016. Inflazome's headquarters is located in Dublin, County Dublin, IE . It has rais...

CEO

Inflazome's Co-Founder & CEO, Matthew Cooper, currently has an approval rating of 89%. Inflazome's primary competitors are Inflection Biosciences, Medexus Pharma, Inc. & Mesoblast Limited.

Website

inflazome.com

Frequently Asked Questions about Inflazome

  1. When was Inflazome founded?

    Inflazome was founded in 2016
  2. Who is Inflazome's CEO?

    Inflazome's CEO is Matthew Cooper
  3. How much revenue does Inflazome generate?

    Inflazome generates $1.7M in revenue
  4. How much funding does Inflazome have?

    Inflazome has historically raised $64M in funding
  1. Where is Inflazome's headquarters?

    Inflazome's headquarters is in Dublin County Dublin, IE
  2. How many employees does Inflazome have?

    Inflazome has 7 employees
  3. What sector does Inflazome operate in?

    Inflazome is in Biotechnology
  4. Who are Inflazome's competitors?

    Inflazome's top competitors are Inflection Biosciences, Medexus Pharma, Inc., Mesoblast Limited